title: [Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors].
abstract: OBJECTIVE
  To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits chemotherapy.
  
  
  METHODS
  Retrospective observational study including all patients with solid tumors who were treated with eltrombopag for thrombocytopenia during the chemotherapy treatment between January 2012 and December 2014.
  
  
  RESULTS
  Six patients, with solid tumors and thrombocytopenia that limits chemotherapy treatment, received eltrombopag during the study and it was observed a decrease in the delay of chemotherapy cycles (4.83 ± 4.79 delayed cycles before starting eltrombopag vs 2.50 ± 4.32 delayed cycles during the treatment with eltrombopag, p=0.492) and an increase in the percentage of administrated dosage (89.29 ± 13.36% vs 91.43 ± 10.69%, p=0.682). Also, there was an increase in platelet nadir (55.29 ± 16.45x10⁹/L vs 76.14 ± 36.38x10⁹/L, p=0.248) without platelet transfusion support in any patient during treatment with eltrombopag.
  
  
  CONCLUSIONS
  eltrombopag has resulted to be an alternative in the treatment of patients with thrombocytopenia that limits chemotherapy, clinical trials with more number or patients are needed to confirm these results.
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Santa Lucía. Cartagena.. henar_oxean@hotmail.com.
authors.forename: María Henar
authors.initials: MH
authors.lastname: García Lagunar
authors.affiliation: Servicio de Oncología Médica. Hospital General Universitario Santa Lucía. Cartagena.. henar_oxean@hotmail.com.
authors.forename: Pablo
authors.initials: P
authors.lastname: Cerezuela Fuentes
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Santa Lucía. Cartagena.. henar_oxean@hotmail.com.
authors.forename: Mónica
authors.initials: M
authors.lastname: Martínez Penella
authors.affiliation: Servicio de Hematología. Hospital General Universitario Santa Lucía. Cartagena. España.. henar_oxean@hotmail.com.
authors.forename: Dolores Paula
authors.initials: DP
authors.lastname: Gutiérrez-Meca Maestre
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Santa Lucía. Cartagena.. henar_oxean@hotmail.com.
authors.forename: María
authors.initials: M
authors.lastname: García Coronel
authors.affiliation: Servicio de Oncología Médica. Hospital General Universitario Santa Lucía. Cartagena.. henar_oxean@hotmail.com.
authors.forename: María José
authors.initials: MJ
authors.lastname: Martínez Ortiz
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D056687:Off-Label Use; D011720:Pyrazoles / Q000627:therapeutic use*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; C520809:eltrombopag